首都医科大学学报 ›› 2014, Vol. 35 ›› Issue (5): 555-559.doi: 10.3969/j.issn.1006-7795.2014.05.006

• 血液病学专题 • 上一篇    下一篇

高白细胞急性髓系白血病TGF-β1的表达及其临床意义

王敏1, 王立茹1, 崔建英1, 周合冰2   

  1. 1. 首都医科大学附属复兴医院血液内科, 北京 100038;
    2. 首都医科大学潞河教学医院血液内科, 北京 101149
  • 收稿日期:2014-08-25 出版日期:2014-10-21 发布日期:2014-10-20
  • 通讯作者: 王立茹 E-mail:wanglirumail@126.com
  • 基金资助:

    2007卫生部公益性行业科研专项(200802031)。

Expression of TGF-β1 in hyperleukocytic acute myeloid leukemia and its clinical significance

Wang Min1, Wang Liru1, Cui Jianying1, Zhou Hebing2   

  1. 1. Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038, China;
    2. Department of Hematology, Luhe Hospital, Capital Medical University, Beijing 101149, China
  • Received:2014-08-25 Online:2014-10-21 Published:2014-10-20
  • Supported by:

    This study was supported by 2007 Department of Health Public Industry Scientific Research(200802031).

摘要:

目的 本文旨在探讨转化生长因子β-1(transform growth factor β1, TGF-β1)在高白细胞急性髓系白血病(acute myeloid leukemia, AML)发病中的作用。方法 分别采用实时定量PCR、流式细胞术及酶联免疫反应检测38例AML患者骨髓单个核细胞(bone marrow mononuclear cells, BMMNC)内TGF-β1 mRNA浓度、48例AML患者BMMNC的TGF-β1蛋白和40例AML患者血清TGF-β1蛋白质量浓度。结果 高白细胞AML患者、非高白细胞AML患者和正常对照者的TGF-β1 mRNA浓度差异无统计学意义,高白细胞和非高白细胞AML患者的胞内TGF-β1蛋白质量浓度显著高于正常对照者,血清TGF-β1蛋白质量浓度显著低于正常对照者。高白细胞和非高白细胞AML患者之间的胞内和血清TGF-β1蛋白质量浓度差异无统计学意义。高白细胞与非高白细胞AML患者之间胞内及血清TGF-β1质量浓度与FAB亚型无关。结论 AML患者血清TGF-β1浓度降低可能参与了疾病的发生,而血清TGF-β1的减少可能并不能反映BMMNC合成TGF-β1减少。TGF-β1对高白细胞AML的发病并未产生重要影响。

关键词: 转化生长因子β-1, 急性髓系白血病, 高白细胞

Abstract:

Objective To investigate the role of transform growth factor β1 (TGF-β1) in pathogenesis of hyperleukocytic acute myeloid leukemia (AML).Methods The mRNA transcription levels of TGF-β1 from bone marrow mononuclear cells (BMMNC) in 38 AML patients, protein expression levels of intracellular TGF-β1 from BMMNC in 48 AML patients, and serum levels of TGF-β1 from 40 AML patients were measured by real-time fluorescence quantitative polymerase chain reaction (RQ-PCR), flow cytometry, and double-antibody sandwich enzyme-linked immunosorbent assay (ELISA), respectively. Results The relative levels of the TGF-β1 gene expression among hyperleukocytic AML patients, non-hyperleukocytic AML patients, and NC has no significant difference (P>0.05). The protein expression levels of TGF-β1 in both hyperleukocytic AML and non-hyperleukocytic AML patients were significantly higher than that in NC (P<0.05), the plasma levels were significantly lower than that in NC (P<0.05). There was no significant difference in intracellular protein expression levels and plasma levels of TGF-β1 between hyperleukocytic AML and non-hyperleukocytic AML patients (P>0.05). There was no significant difference in intracellular protein expression levels and plasma levels of TGF-β1 between the FAB subtypes in hyperleukocytic and non-hyperleukocytic AML (P>0.05). Conclusion Decreased serum levels of TGF-β1 may be involved in the pathogenesis of AML. However, decreased TGF-β1 serum levels may not reflect reduced TGF-β1 production by BMMNC. Our study showed that TGF-β1 had no important impact on the pathogenesis of hyperleukocytic AML.

Key words: transform growth factor β1, acute myeloid leukemia, hyperleukocytic

中图分类号: